KRW 250 bil market shakes from reimb reevaluations
By Chon, Seung-Hyun | translator Kim, Jung-Ju
23.12.28 06:20:26
가나다라
0
Some indications of 3 substances including loxoprofen removed from the reimbursement list as a result of this year’s reimbursement reevaluations
Prescriptions of loxoprofen and epinastine rise after the pandemic…market expected to contract with reduced reimbursement
The KRW 100 billion limaprost alfadex market hit hard by the government’s reimbursement reduction measure.
The pharmaceutical industry has expressed great disappointment regarding the results of the government’s drug reimbursement reevaluations.
The reimbursement scope of three ingredients - loxoprofen, limaprost alpha dex, and epinastine hydrochloride - will be reduced. This is a loss worth KRW 250 billion in the prescription market. The losses felt by pharmaceutical companies are expected to be even greater due to the reimbursement reductions made for products that have seen a surge in their respective prescription markets due to the COVID-19 pandemic and endemic.
This year's reimbursement reevaluations resulted in the indication reduction of 3 substances including loxoprofen... KRW 250 bi
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)